Medication info
Janumet XR 100/1000 mg Extended-Release Tablets

Janumet XR 100/1000 mg Extended-Release Tablets

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
HLB Pharmaceutical Co., Ltd.
Appearance
Bright blue, oval-shaped, bilaterally convex extended-release film-coated tablet
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202073 · Approved 2022.05.17 · Insurance code 647304430

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with meals once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and not split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the stool. It is not known whether the material excreted in the stool contained the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients treated with metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient’s current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients receiving immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be based on the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control, so caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
HLB Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar in patients with type 2 diabetes by combining sitagliptin and metformin. It aids in effectively managing blood sugar levels in conjunction with diet and exercise therapy. This contributes to the prevention of complications arising from diabetes and allows the patient to maintain better health systematically. The role as an adjunctive therapy is very important, and it improves blood sugar control.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with meals once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and not split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the stool. It is not known whether the material excreted in the stool contained the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients treated with metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient’s current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients receiving immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be based on the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control, so caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication contains sitagliptin and metformin for diabetes treatment, so there are several precautions to consider when taking it. First, this medication may cause allergic reactions, so if symptoms such as rash, hives, or difficulty breathing occur, discontinue use immediately and consult a doctor. Additionally, acute pancreatitis, a type of pancreatic inflammation, can rarely occur, so if symptoms such as abdominal pain, nausea, or vomiting develop, inform medical personnel immediately. This medication should not be given to patients with reduced kidney function, and regular tests should be done to ensure normal kidney function. In particular, it may be dangerous to use this medication in patients with moderate to severe kidney impairment, serious infections, dehydration, heart failure, or acute myocardial infarction. It is necessary to halt the use of this medication for a certain period before and after surgery and to restart it only after confirming that kidney function has recovered post-surgery. It is safe to avoid this medication during pregnancy or in breastfeeding women. This medication may induce hypoglycemia, so extra caution is necessary if meals are skipped or irregular, during intense exercise, or when combined with other hypoglycemic agents. Furthermore, alcohol consumption can increase the risk of serious side effects such as lactic acidosis, so it is advisable to avoid drinking while on this medication. During the course of taking this medication, regular monitoring of blood sugar, kidney function, and blood tests is essential, and checking vitamin B12 levels is also necessary. Finally, if any unusual symptoms or discomfort occur during the course of taking this medication, it is vital to consult medical personnel immediately to receive appropriate measures.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 16 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture, and it is crucial to maintain a storage temperature between 1 to 30 degrees Celsius. By storing it this way, the effectiveness of the medication can be safely preserved for an extended period.

Appearance and packaging

Appearance

Bright blue, oval-shaped, bilaterally convex extended-release film-coated tablet

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.